Key Takeaways
- Record quarter, measured tone: Q2 sales and profits exceeded any full-year figure from just 6-7 years ago, driven by oncology outsourcing, softgel growth, and Caplin Steriles’ scale-up. Management remains confident but declined to quantify near-term revenue targets.
- Gross margins spike, but not the new normal: Gross margin hit 57.4% on a favorable product mix, yet management guided investors back to a sustainable 55-56% range.
- The capex super-cycle is on track: All six projects in the ₹600-650 Crores plan are targeted for completion by Q3 FY25, with the high-speed Bosch line already running commercial batches.
- Caplin Steriles is the growth engine: First-half sales surpassed the entity’s full-year revenue from two years ago, and the new US front-end subsidiary sets the stage for a B2C push within 6-9 months.
- What to watch next quarter: The pace of ANDA filings and R&D spend (which spiked other expenses this quarter), the conversion of ₹95 crores of in-transit inventory into Q4 sales, and any further color on the Mexico front-end buildout.
Caplin Steriles: The Growth Engine
- Scale-up milestone: First-half sales of Caplin Steriles this year are greater than the entity’s full-year sales from just two years ago, signaling a steep ramp-up.
- US front-end established: A new subsidiary, Caplin Steriles USA Incorporated in New Jersey, has been set up to sell under the company’s own label, targeting a B2C model in Tier-2 and Tier-3 channels outside large GPOs.
- Revenue timeline: Management expects to start seeing some revenue from the US front-end in the next 6 to 9 months, with year two likely more meaningful than year one.
- Profitability masked by accounting: Reported EBITDA margins are depressed because the company expenses all R&D, filing fees, and ANDA fees immediately rather than capitalizing them. If those expenses were removed, EBITDA margins would be “very similar to the parent company’s number.”
- $100 million ambition: Management is targeting $100 million in revenue for Caplin Steriles by FY2027 and remains confident they can reach this figure or get “very, very close.”
Vivek Partheeban: “We do not want to go to the very large GPOs and distributors and then try and sell our product because that is a space that sort of crowded with big boys, right including the Lupins of the world. What we want to do is there is a certain amount of markets... anywhere between 20% to 30% that is outside of these large GPOs and IDMs... we can actually sell our product even if it is smaller volumes we can actually sell it to for higher margins.”
Capex & Capacity Expansion
- Bosch line operational: Line 5, a high-speed Bosch line, is now running commercial batches. Its speed is more than double the existing line, higher than both existing lines combined.
- Line 1 replacement: The legacy line one will be replaced with another Bosch line, more than doubling existing capacity.
- Prefilled syringe line: Qualifications are ongoing and the line is expected to be completed before the end of this financial year.
- All projects timeline: All six projects in the ₹600-650 Crores plan are targeted for completion by Q3 FY2025 (12 months from the call date). However, qualification, licensing, and commercialization ramp-up will take an additional ~6 months beyond that.
- Oncology facility: The oncology tablet and capsule facility is approximately 3 months away from completion, with commercial production expected to start in the next six months.
- API facility in Vizag: Expected to be completed in six to eight months, or a maximum of nine months.
- Capex spend confusion: When asked how much of the ₹600-650 Crores has been spent, management gave conflicting answers, first citing ₹459 Crores spent plus ₹370 Crores visible, then saying more than half has been spent.
Margin Quality & Sustainability
- Gross margin spike: Gross margins improved from 54.3% to 57.4% due to a favorable mix of niche products: the second softgel line is operational, value-added products are contributing, and oncology orders are strong.
- Not the new normal: Management explicitly guided that 57.4% is not sustainable long-run, with a realistic estimate of 55-56% gross margin and 24-25% PAT.
- Other expenses spike: Q2 other expenses rose to ₹73 Crores from ₹55 Crores in Q1 because the company filed more than 3 ANDAs this quarter, each costing ~₹2 Crores, and R&D expenses increased.
- Cash deployment: Cash is held in fixed deposits yielding 5.5-6% tax-free in Hong Kong, equivalent to a pre-tax return of 8% in India. Interest income has risen substantially, and cash is kept for capex and potential M&A.
- Fiscal discipline pledge: Management committed to staying debt-free and focusing on cash flow, bottomline, and topline in that order.
C.C. Paarthipan: “What is important, what cannot be cured must be endured and endurance is the key. When we have the great, definitely whatever delay which happens actually eventually it will be complete... we have not been borrowing money from any bank it is all happening from our own internal accrual.”
Working Capital & Balance Sheet
- Inventory build is temporary: Inventory increased because it sits next to customers in warehouses and in transit. ₹95 crores of inventory in transit over subsidiaries will convert to sales in Q4.
- Receivables timing: Receivables are slightly higher because Caplin Steriles surpassed its entire H1 revenue from the prior year; payments are expected to realize in November and December.
- No credit losses: Management stated there are no bad debts or unrealized amounts, and inventory has no expired or obsolete stock beyond a very minuscule percentage.
- LATAM disruption: A 10-15 day political disruption in Guatemala caused a temporary halt in medicine purchases, contributing to a slight dip in Q2 LATAM revenue to ₹335 Crores from Q1’s ₹350 Crores. This is considered a rounding issue, not a trend.
New Geographies & Business Development
- Mexico front-end: The company will assemble its own field force in Mexico while focusing on product registration, which takes 9-12 months. Meaningful revenue is expected in about 18 months and beyond.
- Mexico revenue potential: With 100 products registered over 2.5-3 years, Mexico could reach $75-100 million. Tender business will be done through partners who can influence decision-makers.
- CPhI Barcelona: The company generated almost 1,000 new contacts in geographies where it is not currently present. Even a 1% conversion rate would create meaningful new revenue streams.
- Saudi pipeline: The pipeline for Saudi Arabia could be worth as much as $80 million.
- Chile warehouse: A warehouse in Chile will open shortly.
- INVIMA approval: INVIMA approval has come through for Caplin Steriles, opening the Colombian market.
- Outsourcing partnerships: Two companies from India and one from China have been identified to provide dossiers for filing in Caplin’s name; outsourcing will start when products get approved.
Product Pipeline & R&D
- Rocuronium Bromide approval: Received approval for Rocuronium through Lupin as a marketing partner on a non-exclusive deal, with at least one other licensee for the same product.
- Ophthalmic approvals: Two to three more ophthalmic product approvals are expected in the next three to five months.
- Niche filing pipeline: Over the next six months, the company will file niche differentiated products including injectable emulsions, injectable suspensions, ophthalmic emulsions, and injections in plastic vials, with 20-odd products planned over the next 2 to 2.5 years.
- Global product focus: Products will be developed and filed based on global sales potential, not just the US, including evergreen products like Propofol and Enoxaparin, for which the company has developed its own API.
- Oncology already supplying: Over the last 6+ months, several oncology products have been supplied to emergency tenders and private markets in one or two markets, even before the new oncology facility is complete.
- Revenue mix shift: The 70:30 milestone-to-product revenue mix will tilt more toward product revenue (80:20) over the mid-term as the company’s own front end gets established and fewer exclusive licensing deals are done.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin normalization | Sustainable level is 55-56% (vs 57.4% in Q2) | Long-run |
| PAT margin normalization | Sustainable level is 24-25% | Long-run |
| All six capex projects completed | ₹600-650 Crores plan fully executed | Q3 FY2025 |
| Oncology tablet/capsule commercial production | Start of commercial batches | Within 6 months |
| API facility in Vizag completed | Facility ready | 6-9 months |
| Caplin Steriles US own-label revenue | First revenue from US front-end | 6-9 months |
| Prefilled syringe line qualified | Qualifications complete | Before end of FY2024 |
| Caplin Steriles revenue target | $100 million | FY2027 |
| Mexico meaningful revenue | Own front-end generating material sales | ~18 months and beyond |
| Ophthalmic product approvals | 2-3 additional approvals | 3-5 months |
| Revenue aspiration | ₹2,000 Crores sales | FY2024-25 |
| Revenue aspiration | ₹4,000-5,000 Crores sales | 5 years out |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue (H1 FY24) | ₹838 cr, close to FY2020 full-year revenue of ₹863 cr |
| PAT (H1 FY24) | ₹219 cr, surpassed FY2020 full-year PAT of ₹215 cr |
| Gross margin | 57.4%, up from 54.3% YoY; driven by niche products, oncology, and soft gels |
| EBITDA margin | 35.4%, up from 32.4% YoY |
| EBIT margin | 32.6%, up from 29.3% YoY |
| PAT margin | 26.3%, up from 24.2% YoY |
| Cash and cash equivalents | ₹825 cr, held in fixed deposits |
| Receivable days | 103 days, up from 97 days; ₹110 cr collected in Oct and Q3 to date |
| Caplin Steriles revenue | ₹75 cr in Q2, up from ₹46 cr in Q1 |
| Caplin Steriles EBITDA | ₹10 cr in Q2, up from ₹2.5 cr in Q1; after expensing all R&D and ANDA fees |
| LATAM revenue | ₹335 cr in Q2, marginal dip from ~₹350 cr in Q1 due to temporary Guatemala disruption |
| ANDAs under review with FDA | 13, of which 11 in Caplin Steriles name; includes 6 ophthalmic, 4 premixed bags, 3 injectables |
| Capex spent (last 3 years) | ₹459 cr; additional ₹370 cr identified for next 12-18 months, of which ₹200-250 cr crystallized |
| Products registered in Central America & Caribbean | 550 to 560 across six to seven countries |
| Saudi pipeline potential | $80 million |